Open AccessBictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Author(s) -
J. Gallant,
A. Lazzarin,
A. Mills,
C. Orkin,
D. Podzamczer,
P. Tebas,
P.-M. Girard,
I. Brar,
E.S. Daar,
David A. Wohl,
J. Rockstroh,
X. Wei,
J. Custodio,
K. White,
H. Martin,
A. Cheng,
E. Quirk
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/bz5a-cm51
Subject(s) - dolutegravir , abacavir , emtricitabine , tenofovir alafenamide , medicine , lamivudine , human immunodeficiency virus (hiv) , tenofovir , virology , antiretroviral therapy , viral load , virus , hepatitis b virus